Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC - Report - MDSpire

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC

  • By

  • Lorenzo De Sanctis

  • Riccardo Ray Colciago

  • Giulia Rossano

  • Matteo Ferrari

  • Matteo Mombelli

  • Ilenia Manno

  • Federica Ferrario

  • Sara Saufi

  • Valeria Faccenda

  • Denis Panizza

  • Gaia Passarella

  • Stefania Canova

  • Diego Luigi Cortinovis

  • Stefano Arcangeli

  • May 25, 2026

  • 0 min

Share

Clinical Report: Ablative Radiotherapy Targeted at Progression Enhances Event-Free Survival in Oligoprogressive Non-Small Cell Lung Cancer

Overview

This study evaluates the efficacy of progression-directed radiation therapy (PDRT) in patients with oligoprogressive non-small cell lung cancer (NSCLC). Findings indicate that PDRT may improve event-free survival (EFS) and extend the time to next systemic therapy.

Background

Oligoprogression represents a clinical scenario where a limited number of metastatic lesions progress while the majority of the disease remains controlled on systemic therapy. This condition is increasingly recognized as a relevant state for local ablative therapies, which may help delay systemic treatment changes. Understanding the role of PDRT in this context is crucial for optimizing treatment strategies in NSCLC.

Data Highlights

ParameterValue
Median Age68 years
Median Follow-Up14 months
One-Year Actuarial EFS Rate52.1% (95% CI: 46.4–57.8)
Median Time to Next Treatment8 months
Median Progression-Free Survival5 months

Key Findings

  • PDRT was administered after first-line systemic therapy in 70.1% of patients.
  • 13.8% of patients achieved a complete response, while 33.3% had a partial response.
  • Multivariate analysis showed PDRT directed at the primary tumor significantly improved EFS (HR = 0.28).
  • Chemotherapy use was associated with worse outcomes (HR = 2.33).
  • The median EFS was 5 months, with a median time to next treatment of 8 months.

Clinical Implications

The findings suggest that PDRT can be an effective strategy for managing oligoprogressive NSCLC, potentially delaying the need for systemic therapy. Clinicians should consider PDRT in selected patients with oligoprogression to optimize disease control.

Conclusion

PDRT demonstrates promise in enhancing EFS and extending the time to subsequent treatments in patients with oligoprogressive NSCLC. Further studies are needed to validate these results in larger cohorts.

Related Resources & Content

  1. ASTRO/ESTRO Guideline on Oligometastatic NSCLC - American Society for Radiation Oncology (ASTRO), 2023 -- Clinical Practice Guidelines
  2. Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial, PubMed, 2025 -- Study Findings
  3. Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression - Randomised Study, PMC, 2023 -- Study Results
  4. The ASCO Post — Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC
  5. The ASCO Post — EGFR-Mutated NSCLC: Continuing Osimertinib Plus Chemotherapy Through Disease Progression Improves PFS
  6. The ASCO Post — Accelerated Hypofractionated Chemoradiation With Adaptive SABR Boost in Locally Advanced, Unresectable NSCLC
  7. The ASCO Post — Local Consolidative Therapy Linked to Survival Benefit in Oligometastatic Non–Small Cell Lung Cancer
  8. Risk-Adapted Radioimmunotherapy for Locally Advanced PD-L1–Positive NSCLC
  9. EGFR-Mutated NSCLC: Continuing Osimertinib Plus Chemotherapy Through Disease Progression Improves PFS
  10. Accelerated Hypofractionated Chemoradiation With Adaptive SABR Boost in Locally Advanced, Unresectable NSCLC
  11. ASTRO/ESTRO Guideline on Oligometastatic NSCLC - American Society for Radiation Oncology (ASTRO)
  12. Consolidative Use of Radiotherapy to Block (CURB) Oligoprogression - Randomised Study of Standard-of-Care Systemic Therapy with or without Stereotactic Body Radiotherapy in Patients with Oligoprogressive Cancers of the Breast and Lung - PMC
  13. Stereotactic Ablative Radiation for Oligoprogressive Cancers: Results of the Randomized Phase 2 STOP Trial - PubMed
  14. NRG-LU002: Randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy (LCT) plus maintenance systemic therapy for limited metastatic non-small cell lung cancer (NSCLC). | Journal of Clinical Oncology
  15. Stereotactic ablative radiotherapy for oligoprogressive solid tumours: A systematic review and meta-analysis - ScienceDirect
  16. Management of oligometastatic and oligoprogressive epidermal growth factor receptor mutated non-small cell lung cancer patients: state of the art of a combined approach - PubMed
  17. Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized Study - PMC

Original Source(s)

Progression-directed ablative radiotherapy improves event-free survival in oligoprogressive NSCLC

  • by Lorenzo De Sanctis, Riccardo Ray Colciago, Giulia Rossano, Matteo Ferrari, Matteo Mombelli, Ilenia Manno, Federica Ferrario, Sara Saufi, Valeria Faccenda, Denis Panizza, Gaia Passarella, Stefania Canova, Diego Luigi Cortinovis, Stefano Arcangeli

  • May 25, 2026

Related Content

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Retraction: MicroRNA-935 directly targets FZD6 to inhibit the proliferation of human glioblastoma and correlate to glioma malignancy and prognosis

  • May 28, 2026

From molecular networks to translational intervention: current progress in the mechanisms of gemcitabine resistance in bladder cancer